174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. (December 2022)

Record Type:: Journal Article
Title:: 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. (December 2022)
Main Title:: 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data
Authors:: Naing, A.
Wang, J.S.
Sharma, M.R.
Sommerhalder, D.
Gandhi, L.
Oh, D-Y.
Jiang, Y.
Michalski, J.
Lee, J.
Zhou, K.
Taylor, N.
Yan, L.
Roda, J.M.
Blum, L.
Ling, L.
Mikaelian, I.
Depaoli, A.M.
Hanes, V.
Kaplan, D.D.
Lieu, H.D.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100286 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24744.xml